4.41 USD
+0.05 (+1.15%)
At close: Jan 30, 2026
4.25 USD
-0.16 (-3.63%)
After Hours: 1/30/2026, 8:15:33 PM
Overall RCEL gets a fundamental rating of 2 out of 10. We evaluated RCEL against 524 industry peers in the Biotechnology industry. RCEL may be in some trouble as it scores bad on both profitability and health. RCEL shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
- In the past year RCEL has reported negative net income.
- RCEL had a negative operating cash flow in the past year.
- RCEL had negative earnings in each of the past 5 years.
- RCEL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -76.19%, RCEL is doing worse than 65.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -76.19% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-45.47%
ROA(5y)-41.71%
ROE(3y)-492.75%
ROE(5y)-311.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- RCEL has a Gross Margin of 84.81%. This is amongst the best in the industry. RCEL outperforms 87.62% of its industry peers.
- In the last couple of years the Gross Margin of RCEL has grown nicely.
- RCEL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, RCEL has more shares outstanding
- Compared to 1 year ago, RCEL has a worse debt to assets ratio.
2.2 Solvency
- RCEL has an Altman-Z score of -8.96. This is a bad value and indicates that RCEL is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -8.96, RCEL is doing worse than 70.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.96 |
ROIC/WACCN/A
WACC9.93%
2.3 Liquidity
- RCEL has a Current Ratio of 0.67. This is a bad value and indicates that RCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
- RCEL has a worse Current ratio (0.67) than 88.76% of its industry peers.
- RCEL has a Quick Ratio of 0.67. This is a bad value and indicates that RCEL is not financially healthy enough and could expect problems in meeting its short term obligations.
- RCEL's Quick ratio of 0.55 is on the low side compared to the rest of the industry. RCEL is outperformed by 89.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.67 | ||
| Quick Ratio | 0.55 |
3. Growth
3.1 Past
- RCEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.83%, which is quite good.
- The Revenue has grown by 20.59% in the past year. This is a very strong growth!
- The Revenue has been growing by 30.02% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)18.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)20.59%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%-12.71%
3.2 Future
- RCEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.53% yearly.
- The Revenue is expected to grow by 38.78% on average over the next years. This is a very strong growth
EPS Next Y36.05%
EPS Next 2Y27.73%
EPS Next 3Y23.03%
EPS Next 5Y30.53%
Revenue Next Year7.58%
Revenue Next 2Y13.44%
Revenue Next 3Y29.38%
Revenue Next 5Y38.78%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- RCEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCEL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as RCEL's earnings are expected to grow with 23.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.73%
EPS Next 3Y23.03%
5. Dividend
5.1 Amount
- RCEL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AVITA MEDICAL INC / RCEL FAQ
What is the ChartMill fundamental rating of AVITA MEDICAL INC (RCEL) stock?
ChartMill assigns a fundamental rating of 2 / 10 to RCEL.
What is the valuation status of AVITA MEDICAL INC (RCEL) stock?
ChartMill assigns a valuation rating of 1 / 10 to AVITA MEDICAL INC (RCEL). This can be considered as Overvalued.
Can you provide the profitability details for AVITA MEDICAL INC?
AVITA MEDICAL INC (RCEL) has a profitability rating of 1 / 10.